Clinical trial
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
NCT05605964
Study timeline
Study start (actual)2023-01-28Date precision: day
Registry last updated2026-06-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
RelugolixDRUG · verified · RxNorm: relugolix
Leuprolide AcetateDRUG · verified · RxNorm: leuprolide acetate
Sponsors & collaborators
Sumitomo Pharma America, Inc.lead sponsor
Mapped research locations
TampaFlorida, United States3JacksonvilleFlorida, United States3WichitaKansas, United States3ChicagoIllinois, United States2St LouisMissouri, United States2San AntonioTexas, United States2Washington D.C.District of Columbia, United States2TorranceCalifornia, United States2AugustaGeorgia, United States2BillingsMontana, United States2BoiseIdaho, United States2HoustonTexas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05605964 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.